
In a recent interview, Jeremie Calais, MD, PhD, shared his perspective on recent research that compared the risk stratification capabilities of nomogram models incorporating PSMA PET data to established clinical risk scoring models from the European Association of Urology and the National Comprehensive Cancer Network (NCCN).


























